← All organizations
Highest phase reached
Phase 4
First clinical trial
Feb 1, 2008Last known activity
Aug 22, 2025
Timeline
1940s
- Jun 1, 1945
JW Pharmaceutical— Founded
Drugs by trial phase (44 distinct, 58 trials)
Phase 4 (12 own, 0 via acquisition)
Phase 3 (17 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Phase 1 (14 own, 0 via acquisition)
Indications
Studied for
- Anemia
- Anemia, Iron-Deficiency
- Angina Pectoris
- Angina, Stable
- Arthritis
- Arthritis, Rheumatoid
- Deficiency Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Dyslipidemias
- Erectile Dysfunction
- Gout
- Heart Failure
- Hypercholesterolemia
- Hyperlipidemias
- Hyperlipoproteinemias
- Hyperplasia
- Hypertension
- Hypertrophy
- Hyperuricemia
- Infarction
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Lower Urinary Tract Symptoms
- Metabolic Syndrome
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myocardial Infarction
- Neoplasms, Plasma Cell
- Nocturia
- Preleukemia
- Primary Myelofibrosis
- Prostatic Hyperplasia
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Syndrome
- Ureteral Calculi
- Ureterolithiasis
- Urinary Bladder, Neurogenic
Recent trials (50)
- NCT07036458Lead sponsorPhase 1Aug 22, 2025
- NCT06955104Lead sponsorPhase 3Apr 3, 2025
- NCT06703710Lead sponsorPhase 1Jan 31, 2025
- NCT06643130OfficialPhase 3Nov 30, 2024
- NCT06665425Lead sponsorPhase 1Nov 30, 2024
- NCT06643130Lead sponsorPhase 3Nov 30, 2024
- NCT06816719Lead sponsorPhase 1Sep 2, 2024
- NCT06435442Lead sponsorPhase 1May 31, 2024
- NCT06378684Lead sponsorPhase 1Sep 10, 2023
- NCT05815901Lead sponsorPhase 3Mar 14, 2023
- NCT05814406Lead sponsorPhase 3Jan 12, 2023
- NCT05198778Lead sponsorPhase 1Nov 29, 2021
- NCT05331014Lead sponsorPhase 3Nov 15, 2021
- NCT05351840Lead sponsorPhase 1Nov 2, 2020
- NCT05429749CollaboratorPhase 4Jul 30, 2020
Details
- Founded
- Seoul, KR Jun 1, 1945
- Last known activity
- Aug 22, 2025